Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Niessner

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 24, 2025
Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsyTeresa Amaral, Eftychia Chatziioannou, Alica Nuebling, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2023
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)Teresa Amaral, Tobias Sinnberg, Eftychia Chatziioannou, et al.
Cancers|August 23, 2020
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma PatientsFranz J Hilke, Tobias Sinnberg, Axel Gschwind, et al.
Molecular Cancer Research : MCR|May 11, 2018
YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMTCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
The American Journal of Pathology|July 18, 2020
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic TumorsMaximilian Gassenmaier, Maximilian Rentschler, Birgit Fehrenbacher, et al.
Ebiomedicine|July 19, 2016
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to VemurafenibTobias Sinnberg, Elena Makino, Marcel A Krueger, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 21, 2018
6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma CellsSascha Venturelli, Heike Niessner, Tobias Sinnberg, et al.
American Journal of Clinical Dermatology|May 4, 2023
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based ImmunotherapyEftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2024
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapyFrancisco Meraz-Torres, Heike Niessner, Sarah Plöger, et al.
Cancers|March 1, 2020
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal MelanomaAndrea Forschner, Franz-Joachim Hilke, Irina Bonzheim, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|April 24, 2025
Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsyTeresa Amaral, Eftychia Chatziioannou, Alica Nuebling, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2023
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)Teresa Amaral, Tobias Sinnberg, Eftychia Chatziioannou, et al.
Cancers|August 23, 2020
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma PatientsFranz J Hilke, Tobias Sinnberg, Axel Gschwind, et al.
Molecular Cancer Research : MCR|May 11, 2018
YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMTCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
The American Journal of Pathology|July 18, 2020
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic TumorsMaximilian Gassenmaier, Maximilian Rentschler, Birgit Fehrenbacher, et al.
Ebiomedicine|July 19, 2016
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to VemurafenibTobias Sinnberg, Elena Makino, Marcel A Krueger, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 21, 2018
6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma CellsSascha Venturelli, Heike Niessner, Tobias Sinnberg, et al.
American Journal of Clinical Dermatology|May 4, 2023
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based ImmunotherapyEftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2024
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapyFrancisco Meraz-Torres, Heike Niessner, Sarah Plöger, et al.
Cancers|March 1, 2020
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal MelanomaAndrea Forschner, Franz-Joachim Hilke, Irina Bonzheim, et al.
Pageof 6